DPI developer Pulmatrix has hired Margaret Wasilewski as its Chief Medical Officer, the company said. Wasilewski most recently offered consulting services as President of ID Remedies, and her previous experience includes clinical development positions at Shire, Tetraphase Pharmaceuticals, Targanta Therapeutics, and Eli Lilly.
Pulmatrix’s pipeline includes Pulmazole intraconazole DPI (PUR 1900) for the treatment of allergic bronchopulmonary aspergillosis (ABPA) in asthma patients, PUR 3100 dry powder dihydroergotamine (DHE) for the treatment of migraine, and PUR 1800, a kinase inhibitor licensed from the Lung Cancer Initiative (LCI) at Johnson & Johnson, for acute exacerbations in COPD.
Pulmatrix CEO Ted Raad commented, “We are proud to welcome Dr. Wasilewski to the Pulmatrix Executive Team. She brings extensive experience across different stages of pharmaceutical drug development in various therapeutic areas. Pulmatrix will immediately benefit from her leadership in the clinical strategy and delivery of the clinical trial milestones. She will also be my partner in charting the direction of our current and future pipeline. I am excited about the deep capabilities that Dr. Wasilewski will add to the Pulmatrix team as we look to further develop our pipeline.”
Wasilewski responded, “I am thrilled to join Pulmatrix at such an exciting time. The current pipeline has potential to address important unmet needs in both respiratory and neurological disease, while the iSPERSE technology provides opportunity to expand into new areas of unmet need. I look forward applying my experience to position Pulmatrix for long-term success.”
Read the Pulmatrix press release.
